Is a clinically validated genetic screening test based on Next-Generation Sequencing (NGS).
Allows for testing of all known recessive conditions, increasing the overall detection rate and minimizing the global residual risk.
Maximizes IVF applications, matching possible with all genetic lab tests in the market.
Our different CGT options, tailored to each patient’s needs, make it the most complete test available.
Any upgrade possible at a later date if required.
Exome sequencing offers added value for a future analysis of a given patient providing analytical possibilities in an adverse event of a newborn with a genetic condition.
Who should use CGT test?
Couples who plan on forming a family and want to know the risk of transmitting hereditary disorders to their children
Patients planning an assisted reproduction treatment
Patients planning a treatment with donor sperm or eggs
Most carriers of genetic mutations don’t have a family history of these disorders.
The sensitivity of the test is 98%.
We only analyze genes on the list available at www.cgt.igenomix.com, reporting results based on knowledge current at the time of testing. Therefore, only genes included in this list will be detected.
The method is based on analysis by massive parallel sequencing and bioinformatics, studying all the exons of the genes included on our gene list. This includes adjacent intronic regions before or after position +5 and -5. Variants located outside the gene regions studied, such as gene-expression regulatory regions or intronic regions before or after position +5 and -5 are not detected.
No inversions, deletions, or duplications over 20 nucleotides long that are not referred to in the list available at www.cgt.igenomix.com are studied.
Germ mosaics (mutations only present in gametes) are not detected by this analysis because the DNA material studied is obtained from a blood sample.
A negative result for the genes indicated does not exclude the possibility that a de novo mutation may appear in the offspring.
The development of the CGT panel and the concept of comprehensive carrier screening was published in a paper by Martin et al, 2015 (Fertil Steril. 2015 Nov; 104(5):1286-93).
An analysis of preconception carrier screening and genetic matching with donor gametes was presented in an abstract by Egea et al, 2016 (Fertil Steril. 2016 Oct; e329).
Results discussing the use of carrier screening to predict the risk of disorders in the Middle-Eastern population was published as an abstract by Martin et al, 2018 (Reproductive Biomedicine Online 2018; e10)
We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.